An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy

NCT07573631 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy (DMD)

Interventions

DRUG: BMN 351

Sponsor

BioMarin Pharmaceutical